AstraZeneca US_Health & Fitness

Skip to contentskip to navigation Cookie PolicyThis website uses cookies to helpus give you the best experience when you visit.By using this website you consent to our use of these cookies.Find out more about how we use cookies and how to manage them by reading our cookie notice.CloseSearchMenuSearchCloseAbout UsAstraZeneca in the USCorporate TransparencyResponsible BusinessCommunity ImpactAstraZeneca HealthCare FoundationEmployee Volunteerism and GivingRequest supportSustainabilityPatients & CaregiversAffordabilityAstraZeneca DirectMedicinesPatient ResourcesProduct counterfeitingHealthcare ProvidersMedicinesMedical InformationProduct counterfeitingCareersCareersMediaPress ReleasesStatementsArticlesAZ&You BlogContact UsInside the USOutside the USMoreHideAstraZeneca WebsitesGlobal siteWelcome to AstraZeneca United StatesWe push the boundaries of science to deliver life-changing medicinesAZ&You BlogConversations on Severe Asthma: Realities from the Patient & Advocacy Community3 May 2022National Kidney Month – Speaking with Your Doctor about CKD7 March 2022Meet our 2021 Power of Us Award Winners8 February 2022Portraits of Lung Cancer23 November 2021Nina Parker on Breaking the Cycle of Asthma15 November 2021Latest News from AstraZeneca USENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen5 May 2022FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction5 May 2022ULTOMIRIS® (ravulizumab-cwvz) met primary endpoint in CHAMPION-NMOSD Phase III trial in adults with neuromyelitis optica spectrum disorder5 May 2022Imfinzi plus chemotherapy granted Priority Review in the US for patients with locally advanced or metastatic biliary tract cancer based on TOPAZ-1 Phase III trial4 May 2022ULTOMIRIS® (ravulizumab-cwvz) approved in the US for adults with generalized myasthenia gravis28 April 2022ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US for patients with HER2-low metastatic breast cancer27 April 2022Follow AstraZeneca on Twitter and Facebook@AstraZenecaUS on Twitter AstraZenecaUS@AstraZenecaUSToday, in collaboration with @DaiichiSankyoUS, we announced @US_FDA approval of our treatment for certain patients… https://t.co/honfPJxohtreplyretweet4favorite6May 05AstraZenecaUS@AstraZenecaUSToday, we announced high-level results from the DELIVER Phase III trial evaluating #cardiovascular death or worseni… https://t.co/2ImHonRgLRreplyretweet0favorite7May 05AstraZenecaUS@AstraZenecaUSWe’re excited to unveil this year’s judges in the Cancer Community Awards, part of our #YOURCancer program in partn… https://t.co/XRS6AvQPckreplyretweet2favorite6May 04Follow AstraZenecaUSPascal Soriot calls for global cooperation in the fight against COVID-19 and climate changeCOVID-19 Information Hub BioPharmaceuticalsWe want to transform healthcare, change the lives of billions of people for the better and address some of the biggest healthcare challenges facing humankind. Our ambition is to stop the progress of these often degenerative, debilitating, and life-threatening conditions, achieve remission, and one day cure them.Learn moreOncology: Start with OneAt AstraZeneca, we are leading a revolution in oncology to redefine cancer care for the millions of Americans living with cancer. It’s a lofty ambition. But we know that as with every great journey, the road always starts with one—one indication that can change the course of disease for a patient, one person living with cancer that benefits from our support services, one access barrier that we can help to overcome, one system to transform in partnership with the community—and then another, building from there until success is achieved. Click below to read more about this next chapter.Learn more What science can doIf you are passionate about science, these stories will show you how the latest and most exciting projects we have been working on and the people behind them.Explore more on on our global siteGlobal siteAstraZeneca's global website is intended for people seeking information on AstraZeneca's worldwide business. Click the 'Global site' link for the directory of country sites. ResourcesAstraZeneca in the USCommunity supportAffordabilityAZ&You Blog Quick linksContact us MediaCareersMedicinesSocial MediaTwitterFacebookutility linksPrivacy notice Legal noticeCalifornia supply chains disclosure SitemapCopyright Cookie policy©2022 AstraZenecaYou are now leaving AstraZeneca-us.comYou have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit.Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed.CancelContinue?Important notice for usersYou are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Please refer to your approved national product label (SmPC) for current product information.I have read this warning and will not be using any of the contained product information for clinical purposes.I disagreeI agree??